APA (7th ed.) Citation

ZA, W., YK, K., KW, L., S, Q., K, Y., IH, K., . . . PC, E. (2024). Bemarituzumab as first-line treatment for locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma: Final analysis of the randomized phase 2 FIGHT trial. Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 27(3), 558. https://doi.org/10.1007/s10120-024-01466-w

Chicago Style (17th ed.) Citation

ZA, Wainberg, et al. "Bemarituzumab as First-line Treatment for Locally Advanced or Metastatic Gastric/gastroesophageal Junction Adenocarcinoma: Final Analysis of the Randomized Phase 2 FIGHT Trial." Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 27, no. 3 (2024): 558. https://doi.org/10.1007/s10120-024-01466-w.

MLA (9th ed.) Citation

ZA, Wainberg, et al. "Bemarituzumab as First-line Treatment for Locally Advanced or Metastatic Gastric/gastroesophageal Junction Adenocarcinoma: Final Analysis of the Randomized Phase 2 FIGHT Trial." Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, vol. 27, no. 3, 2024, p. 558, https://doi.org/10.1007/s10120-024-01466-w.